GlaxoSmithKline (GLAXF): Achieved a 5% increase in 2023 sales, with vaccine sales rising notably. Roche (RHHBY): Multiple sclerosis and hemophilia treatments exceeded expectations, supporting dividend...
Source LinkGlaxoSmithKline (GLAXF): Achieved a 5% increase in 2023 sales, with vaccine sales rising notably. Roche (RHHBY): Multiple sclerosis and hemophilia treatments exceeded expectations, supporting dividend...
Source Link
Comments